Amicus Therapeutics

United States
Cranbury, New Jersey, United States, 08512

Company profile

Amicus Therapeutics company profile

Amicus Therapeutics is a biotechnology company that focuses on discovering, developing, and commercializing medicines for rare and genetic diseases. It develops and delivers treatment programs, including oral therapies and combination regimens for specific metabolic conditions such as Fabry and Pompe diseases, and it manages research and licensing activities for additional potential therapies like treatments for focal segmental glomerulosclerosis. The company maintains initiatives that support patient communities affected by rare disorders and collaborates with healthcare and nonprofit organizations to enhance access and advocacy for these disease groups. Amicus also engages in corporate giving programs that support educational, advocacy, and access efforts related to its therapeutic focus areas.

Business identity

Contact email
[email protected]
Phone number
(609)662-200
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Revenue range
$500,000+
Founded
2002-01-01, Year

Headquarters

Postal code
08512
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
20
Total equity funding
$1.4B
Last funding
Post IPO Debt / $400M / 2023-10-02
Last equity funding
Post IPO Equity / $30M
Investors
18
Lead investors
9
Founders
1
Articles
402
Exited on
2007-05-31

Founders and investors

Founders

John Crowley

Lead investors

Blackstone CreditBlackstone Life SciencesCanaan PartnersGlaxoSmithKlineHayfin Capital ManagementMichael J. Fox FoundationMuscular Dystrophy AssociationNew Enterprise AssociatesQuaker BioVentures

Investors

Blackstone CreditCanaan PartnersMichael J. Fox FoundationMidCap FinancialNew Enterprise Associates